Results 21 to 30 of about 6,539 (200)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]

, 2020
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai, Bernstein, Jonathan A, Brusselle, Guy, Castro, Mario, Garin, Margaret, Hickey, Lisa, Humbert, Marc, Jacobs, Joshua, Marsteller, Douglas A, Maspero, Jorge Fernando, McElhattan, Jennifer, Murphy, Kevin, Vanlandingham, Rebecca, Virchow, J Christian   +13 more
core   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis

Respiratory Medicine Case Reports, 2022
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

BMC Pulmonary Medicine, 2020
Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA).
Takanori Numata, Hanae Miyagawa, Saiko Nishioka, Keitaro Okuda, Hirofumi Utsumi, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source

Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]

, 2012
Peer reviewedPublisher ...
Walsh, Garry M.
core   +2 more sources

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

, 2013
Peer reviewedPublisher ...
Bickham U.R., Duval E., Fadok V.A., Fadok V.A., Gaipl U.S., Hart S.P., Luttmann W., Meagher L.C., Schwartz B.R., Walsh G.M.   +9 more
core   +3 more sources

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source